Provided by Tiger Trade Technology Pte. Ltd.

Everus Construction Group, Inc.

97.29
+8.339.36%
Post-market: 97.290.00000.00%16:10 EST
Volume:540.11K
Turnover:51.83M
Market Cap:4.96B
PE:27.49
High:97.63
Open:91.50
Low:90.13
Close:88.96
52wk High:103.08
52wk Low:31.38
Shares:51.01M
Float Shares:50.85M
Volume Ratio:0.68
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.54
EPS(LYR):2.81
ROE:35.26%
ROA:10.41%
PB:8.66
PE(LYR):34.58

Loading ...

University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center

GlobeNewswire
·
Feb 05

Nanchang Mineral Systems to Invest $30 Million in ECG Through Singapore Subsidiary

Stock News
·
Feb 05

Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals

GlobeNewswire
·
Jan 29

Everus Construction Group Inc. to Announce Fourth Quarter and Full-Year Results via Webcast

Reuters
·
Jan 29

Everus Construction Group Inc : Stifel Cuts Target Price to $107 From $110

THOMSON REUTERS
·
Jan 26

A Look At Everus Construction Group (ECG) Valuation After Strong Third Quarter Earnings Surprise

Simply Wall St.
·
Jan 25

Cantor Fitzgerald Initiates Everus Construction at Neutral With $97 Price Target

MT Newswires Live
·
Jan 23

Everus Construction initiated with a Neutral at Cantor Fitzgerald

TIPRANKS
·
Jan 23

Everus Construction Group Initiated at Neutral by Guggenheim

Dow Jones
·
Jan 22

Guggenheim Initiates Coverage on Everus Construction With Neutral Rating

MT Newswires Live
·
Jan 22

Press Release: PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics

Dow Jones
·
Jan 13

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

GlobeNewswire
·
Jan 07

Everus Construction Group (ECG): Assessing Valuation After a 29% One-Year Share Price Gain

Simply Wall St.
·
Dec 23, 2025

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

GlobeNewswire
·
Dec 13, 2025

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

GlobeNewswire
·
Dec 12, 2025

OMRON Healthcare Unveils Global ECG Strategy

prnewswire
·
Dec 11, 2025

Why Is Micro Cap HeartBeam Stock Surging On Wednesday?

Benzinga_recent_news
·
Dec 11, 2025

Director Helena Mercedes Hernandez Acquires Common Shares of Everus Construction Group Inc

Reuters
·
Dec 09, 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

GlobeNewswire
·
Dec 08, 2025

iRhythm Technologies (IRTC) Valuation After New Global Zio ECG Data From Major Cardiac Conference

Simply Wall St.
·
Dec 03, 2025